Company · Private
Tornado Therapeutics
Developing selective TORC1 inhibitors intended to improve immune function in older adults.
Listing
Private
Ticker
—
Headquarters
Boston, US
Founded
2020
Technology
mTOR inhibition / immune aging
Category
Longevity thesis
Selective mTOR inhibition can capture rapamycin's benefits without broad immunosuppression.
Programmes
- TOR-114Phase 2
Respiratory infection in older adults
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.